Skip to main content
OpenTrials
Completed

NCT Number: NCT02447276

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Body mass index ≤39
  • Clinical diagnosis of OA of the knee or hip
  • History of inadequate pain relief or intolerance to analgesics used for OA
  • Moderate to severe pain in the index joint
  • History of regular use of analgesic medications for OA pain
  • Willing to discontinue current non-steroidal anti-inflammatory drug (NSAID) and opioid pain medications

Key Exclusion Criteria:

  • Other diseases that may involve index knee or hip, including inflammatory joint diseases, crystalline disease (gout or pseudogout), endocrinopathies, metabolic joint disease, lupus erythematosus, rheumatoid arthritis, joint infections, neuropathic disorders, avascular necrosis, Paget's disease, renal osteodystrophy or tumors
  • History of osteonecrosis, destructive arthropathy (RPOA), hip dislocation, pathologic fractures, neuropathic joint arthropathy, knee dislocation or hip dislocation
  • Trauma to the index joint in the 30 days before screening
  • Active fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to severe pain that may confound assessments or self-evaluation of the pain associated with OA
  • Prior to the start of the study has received a recommendation for, or is scheduled for joint replacement surgery to be performed during the study period
  • Presence of subchondral insufficiency fracture on screening films or MRI
  • Received an intra-articular injection of hyaluronic acid in the affected index joint within 90 days prior to the screening visit
  • Systemic (ie, oral or intramuscular) corticosteroids within 30 days prior to the screening visit. Intra-articular corticosteroids in the index joint within 12 weeks of the screening visit, or to any other joint within 30 days prior to the screening visit.
  • History of autonomic neuropathy, diabetic neuropathy, or presence of clinically relevant peripheral neuropathy at the time of screening
  • Women of childbearing potential who have a positive pregnancy test result, or who do not have their pregnancy test results at baseline
  • Pregnant or breastfeeding women

Treatment and study plan

REGN475

Drug

Placebo

Drug

Primary outcomes

  1. The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Change from baseline to week 16 in the WOMAC physical function subscale score

    Time frame: Baseline to week 16

  2. Change from baseline to week 16 in the Patient Global Assessment score

    Time frame: Baseline to week 16

  3. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Baseline to week 36 (end of study)

  4. Incidence of anti-REGN475 antibody development

    Time frame: Baseline to week 36 (end of study)

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Registry information

Official study title

A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
May 18, 2015
Registry last updated
Mar 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.